What is Zacks Research’s Forecast for AGIO FY2028 Earnings?

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) – Investment analysts at Zacks Research issued their FY2028 EPS estimates for Agios Pharmaceuticals in a research note issued on Wednesday, March 4th. Zacks Research analyst Team forecasts that the biopharmaceutical company will post earnings per share of ($3.61) for the year. The consensus estimate for Agios Pharmaceuticals’ current full-year earnings is ($6.85) per share.

AGIO has been the topic of a number of other reports. JPMorgan Chase & Co. boosted their price objective on Agios Pharmaceuticals from $20.00 to $25.00 and gave the company a “neutral” rating in a research note on Tuesday, January 6th. Bank of America raised their target price on Agios Pharmaceuticals from $32.00 to $34.00 and gave the stock a “buy” rating in a research note on Wednesday, December 24th. Leerink Partners lifted their target price on Agios Pharmaceuticals from $34.00 to $40.00 and gave the stock an “outperform” rating in a report on Friday, December 26th. The Goldman Sachs Group dropped their price target on Agios Pharmaceuticals from $40.00 to $25.00 and set a “neutral” rating on the stock in a research note on Thursday, November 20th. Finally, Royal Bank Of Canada cut Agios Pharmaceuticals from an “outperform” rating to a “sector perform” rating and cut their price target for the stock from $57.00 to $28.00 in a report on Wednesday, November 19th. Six analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $40.67.

Agios Pharmaceuticals Trading Down 0.8%

Shares of AGIO opened at $27.47 on Friday. The firm’s fifty day simple moving average is $28.05 and its two-hundred day simple moving average is $33.26. Agios Pharmaceuticals has a 12 month low of $22.24 and a 12 month high of $46.00. The stock has a market capitalization of $1.61 billion, a P/E ratio of -3.86 and a beta of 0.89.

Insider Activity

In other Agios Pharmaceuticals news, insider Tsveta Milanova sold 2,932 shares of the firm’s stock in a transaction on Tuesday, December 30th. The shares were sold at an average price of $27.09, for a total value of $79,427.88. Following the transaction, the insider directly owned 29,190 shares of the company’s stock, valued at approximately $790,757.10. This trade represents a 9.13% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Sarah Gheuens sold 2,932 shares of the company’s stock in a transaction dated Tuesday, December 30th. The stock was sold at an average price of $27.09, for a total transaction of $79,427.88. Following the completion of the sale, the insider owned 64,795 shares in the company, valued at $1,755,296.55. This represents a 4.33% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 33,303 shares of company stock valued at $901,977. Corporate insiders own 4.30% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of AGIO. T. Rowe Price Investment Management Inc. purchased a new stake in shares of Agios Pharmaceuticals during the fourth quarter valued at approximately $25,000. Assetmark Inc. boosted its position in Agios Pharmaceuticals by 37.9% in the fourth quarter. Assetmark Inc. now owns 1,317 shares of the biopharmaceutical company’s stock worth $36,000 after purchasing an additional 362 shares during the last quarter. NewEdge Advisors LLC bought a new position in Agios Pharmaceuticals in the 1st quarter valued at $40,000. First Horizon Corp bought a new position in Agios Pharmaceuticals in the 3rd quarter valued at $45,000. Finally, Caitong International Asset Management Co. Ltd purchased a new stake in shares of Agios Pharmaceuticals during the 4th quarter valued at $49,000.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.